|
⚲
|
| Keyboard |
| CPMG Inc
✚
|
|
|---|---|
| CRD # | 131417 |
| SEC # | 801-64945 |
| CIK # | 0001372218 |
| AUM | 855.8 M (2026-03-30) |
| Employees | 7 (29% Investors, 0% Brokers) |
| Phone | 214-871-6829 |
| Address | 4215 West Lovers Lane Dallas, TX 75209 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Inflection Point Acquisition Corp | 23.0 | ||
| Procept Biorobotics Corp | 10.7 | ||
| Instil Bio Inc | 3.4 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Aracari LP | [2025-03-28] | 25.5 M | 64.0 M |
| Filed 2025-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Gyrfalcon LP | [2025-03-28] | 39.7 M | 49.6 M |
| Filed 2025-11-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Icterine LP | [2025-03-28] | 20.6 M | 20.6 M |
| Filed 2026-02-19 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Manakin LP | [2023-08-24] | 26.2 M | 73.3 M |
| Filed 2026-02-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Motmot LP | [2023-08-24] | 36.7 M | 4.9 M |
| Filed 2025-05-15 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Oriole LP | 2023-03-31 | 12.7 M | |
| PE | Canary Partners LP | [2022-08-22] | 36.6 M | 65.4 M |
| Filed 2025-05-20 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Snowy Owl LP | [2022-05-25] | 35.4 M | 40.7 M |
| Filed 2026-01-30 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Cotinga LP | [2022-02-23] | 73.4 M | 90.3 M |
| Filed 2026-02-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Ibisbill LP | [2020-11-16] | 48.0 M | 4.7 M |
| Filed 2025-09-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 26 | 0.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 26 | 0.9 |
| By Discretionary | ||
| Discretionary | 26 | 0.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 0.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.8 | |
| Total | 26 | 0.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Bateman | Executive Officer | 40 | 4 | |
| CPMG Inc | Director, Executive Officer, Promoter | 40 | 4 | |
| R McGaughy | Executive Officer | 30 | 3 | |
| Anthony Miller | Executive Officer | 24 | 3 | |
| James Traweek | Director, Executive Officer | 22 | 3 | |
| Richard McGaughy | Director | 19 | 3 | |
| Ryan Schedler | Executive Officer | 8 | 3 | |
| Condire Investors LLC | Director | 6 | 3 | |
| Antal Desai | Executive Officer | 32 | 2 | |
| Adam Usdan | Executive Officer | 6 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001372218] | |
| 3 | [0001372218] | |
| 4 | [0001372218] | |
| SC 13D | [0001372218] | |
| SC 13G | [0001372218] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| CPMG Inc | Procept Biorobotics Corp | [2021-09-27] |
| CPMG Inc | Instil Bio Inc | [2021-04-01] |
| CPMG Inc | Golden Star Resources Ltd | [2019-02-14] |
| CPMG Inc | Apollo Endosurgery Inc | [2017-01-09] |
| CPMG Inc | Reata Pharmaceuticals Inc | [2016-06-06] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.4B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | FJGXH83P6BIM3DIKIU26 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| PROCEPT BioRobotics Corp | |
| CPMG Inc | |
| White Tailed Ptarmigan LP | |
| McGaughy R Kent Jr | |
| Reata Pharmaceuticals Inc | |
| Desai Antal Rohit | |
| Lpath Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
PROCEPT BioRobotics Corp PRCT
Common Stock
|
2024-05-03 | Other | 1,785,127 | $0.00 | |
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 442,560 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 748,253 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 431,155 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 109,415 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 37,909 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 334,740 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 307,776 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 34,897 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 44,200 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 5,464 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 137,962 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 282,246 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 113 | ||
|
Reata Pharmaceuticals Inc RETA
Class A common stock
|
2023-09-26 | Disposed to issuer | 116,512 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 1,251 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 993,929 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 114,946 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 1,490 | ||
|
Reata Pharmaceuticals Inc RETA
Class B common stock · derivative
|
2023-09-26 | Disposed to issuer | 150,186 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Bow Street LLC
✚
|
NY | 884.7 M |
|
Sandglass Capital Advisors LLC
✚
|
NY | 873.7 M |
|
TREO Asset Management LLC
✚
|
NY | 864.7 M |
|
Eagle's View Capital Management LLC
✚
|
NY | 860.5 M |
|
Arosa Capital Management LP
✚
|
FL | 856.6 M |
|
GFO Asset Management LLC
✚
|
FL | 856.1 M |
|
First Citizens Institutional Asset Management LLC
✚
|
NY | 829.2 M |
|
P2 Capital Partners LLC
✚
|
NY | 824.4 M |
|
MYDA Advisors LLC
✚
|
NY | 821.2 M |
|
Segra Capital Management LLC
✚
|
FL | 820.7 M |